Omeros (NASDAQ:OMER) Given Hold Rating at Needham & Company LLC

Needham & Company LLC reiterated their hold rating on shares of Omeros (NASDAQ:OMER) in a report issued on Thursday morning,Benzinga reports.

A number of other research analysts also recently issued reports on OMER. StockNews.com downgraded Omeros from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Rodman & Renshaw started coverage on Omeros in a research report on Thursday. They set a “buy” rating and a $9.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.00.

Omeros Price Performance

OMER opened at $6.75 on Thursday. The stock’s 50-day moving average price is $4.14 and its 200 day moving average price is $4.10. Omeros has a 12-month low of $1.38 and a 12-month high of $7.51.

Institutional Investors Weigh In On Omeros

Large investors have recently modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Omeros by 2.6% in the first quarter. Vanguard Group Inc. now owns 3,250,284 shares of the biopharmaceutical company’s stock worth $11,213,000 after purchasing an additional 81,348 shares during the period. Geode Capital Management LLC grew its holdings in shares of Omeros by 0.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,339,251 shares of the biopharmaceutical company’s stock valued at $5,318,000 after buying an additional 6,839 shares during the period. State Street Corp boosted its stake in shares of Omeros by 0.3% during the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company’s stock worth $4,867,000 after buying an additional 3,839 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Omeros by 4.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 485,035 shares of the biopharmaceutical company’s stock valued at $1,926,000 after purchasing an additional 18,454 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Omeros by 16.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock valued at $887,000 after acquiring an additional 31,081 shares during the period. 48.79% of the stock is owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.